Triple immunosuppressive therapy in immunologic high-risk renal allograft recipients.
Cole
E
E
St. Michael's Hospital, University of Toronto, Ontario, Canada.
Robinson
C
C
Bear
R
R
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D003524:Cyclosporins / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D006435:Renal Dialysis; D012307:Risk Factors; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D001379:Azathioprine; D011241:Prednisone